Multi-Organ Transplant and HPB Surgical Oncology, Division of General Surgery, University Health Network, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Department of Pediatric Surgery and Transplantation, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
Ann Surg. 2021 Mar 1;273(3):483-493. doi: 10.1097/SLA.0000000000004071.
Transplant oncology defines any application of transplant medicine and surgery aimed at improving cancer patients' survival and/or quality of life. In practice, liver transplantation for selected hepato-biliary cancers is the only solid organ transplant with demonstrated efficacy in curing cancer. Four are the proposed future contributions of transplant oncology in hepato-biliary cancer (4-e). (1) evolutionary approach to cancer care that includes liver transplantation; (2) elucidation of self and non-self recognition systems, by linking tumor and transplant immunology; (3) exploration of innovative endpoints both in clinical and experimental settings taking advantage from the access to the entire liver explant; (4) extension of surgical limitation in the multidisciplinary approach to hepato-biliary oncology. The aim of this review is to define the principles of transplant oncology that may be applied to hepato-biliary cancer treatment and research, attempting to balance current evidences with future opportunities.
移植肿瘤学定义了任何旨在提高癌症患者生存率和/或生活质量的移植医学和外科应用。实际上，针对特定肝胆癌的肝移植是唯一一种被证实可有效治愈癌症的实体器官移植。移植肿瘤学在肝胆癌中有四个未来的可能贡献(4-e)。（1）包括肝移植在内的癌症治疗的演进方法；（2）通过将肿瘤和移植免疫学联系起来，阐明自我和非自我识别系统；（3）利用整个肝移植标本的获取，在临床和实验环境中探索创新的终点；（4）在肝胆肿瘤的多学科方法中扩大手术的局限性。本综述的目的是定义可应用于肝胆癌治疗和研究的移植肿瘤学原则，尝试在当前证据和未来机会之间取得平衡。
